The PI3K/Akt/FOXO3a/p27Kip1 signaling contributes to anti-inflammatory drug-suppressed proliferation of human osteoblasts

Biochemical Pharmacology

Volumn 79, Issue 6, 2010, Pages 926-937

  Li, Ching Ju ^a,b   Chang, Je Ken ^a,b,c   Chou, Chia Hsuan ^b   Wang, Gwo Jaw ^a,b,c   Ho, Mei Ling ^a,b  

^a Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Anti inflammatory drugs; Forkhead box O (FOXO); Human osteoblasts; p27Kip1; PI3K Akt signal transduction; Proliferation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; INDOMETACIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LEVEL; CELL NUCLEUS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; OSTEOBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEXTROAMPHETAMINE; EPIDERMAL GROWTH FACTOR; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INDOMETHACIN; MALE; MORPHOLINES; OSTEOBLASTS; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SULFONAMIDES;

EID: 74149083167     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.019     Document Type: Article

References (76)

1. Cooper C., Coupland C., and Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54 (1995) 49-52
2. Saag K.G., Koehnke R., Caldwell J.R., Brasington R., Burmeister L.F., Zimmerman B., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96 (1994) 115-123
3. Verstraeten A., and Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 45 (1986) 852-857
4. Ho M.L., Chang J.K., and Wang G.J. Antiinflammatory drug effects on bone repair and remodeling in rabbits. Clin Orthop (1995) 270-278
5. Ho M.L., Chang J.K., and Wang G.J. Effects of ketorolac on bone repair: a radiographic study in modeled demineralized bone matrix grafted rabbits. Pharmacology 57 (1998) 148-159
6. Boursinos L.A., Karachalios T., Poultsides L., and Malizos K.N. Do steroids, conventional non-steroidal anti-inflammatory drugs and selective Cox-2 inhibitors adversely affect fracture healing?. J Musculoskelet Neuronal Interact 9 (2009) 44-52
7. O'Connor J.P., and Lysz T. Celecoxib, NSAIDs and the skeleton. Drugs Today (Barc) 44 (2008) 693-709
8. Vuolteenaho K., Moilanen T., and Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 102 (2008) 10-14
9. Goldberg Y., Nassif I.I., Pittas A., Tsai L.L., Dynlacht B.D., Rigas B., et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12 (1996) 893-901
10. Piazza G.A., Rahm A.K., Finn T.S., Fryer B.H., Li H., Stoumen A.L., et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57 (1997) 2452-2459
11. Shiff S.J., Koutsos M.I., Qiao L., and Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222 (1996) 179-188
12. Zhang G., Tu C., Zhou G., and Zheng W. Indomethacin induces apoptosis and inhibits proliferation in chronic myeloid leukemia cells. Leuk Res 24 (2000) 385-392
13. Corroyer S., Schittny J.C., Djonov V., Burri P.H., and Clement A. Impairment of rat postnatal lung alveolar development by glucocorticoids: involvement of the p21CIP1 and p27KIP1 cyclin-dependent kinase inhibitors. Pediatr Res 51 (2002) 169-176
14. Fernandes D., Guida E., Koutsoubos V., Harris T., Vadiveloo P., Wilson J.W., et al. Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle. Am J Respir Cell Mol Biol 21 (1999) 77-88
15. Weinstein R.S., Jilka R.L., Parfitt A.M., and Manolagas S.C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102 (1998) 274-282
16. Weinstein R.S., and Manolagas S.C. Apoptosis and osteoporosis. Am J Med 108 (2000) 153-164
17. Chang J.K., Wang G.J., Tsai S.T., and Ho M.L. Nonsteroidal anti-inflammatory drug effects on osteoblastic cell cycle, cytotoxicity, and cell death. Connect Tissue Res 46 (2005) 200-210
18. Ho M.L., Chang J.K., Chuang L.Y., Hsu H.K., and Wang G.J. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol 58 (1999) 983-990
19. Chang J.K., Li C.J., Wu S.C., Yeh C.H., Chen C.H., Fu Y.C., et al. Effects of anti-inflammatory drugs on proliferation, cytotoxicity and osteogenesis in bone marrow mesenchymal stem cells. Biochem Pharmacol 74 (2007) 1371-1382
20. Chang J.K., Li C.J., Liao H.J., Wang C.K., Wang G.J., and Ho M.L. Anti-inflammatory drugs suppress proliferation and induce apoptosis through altering expressions of cell cycle regulators and pro-apoptotic factors in cultured human osteoblasts. Toxicology 258 (2009) 148-156
21. Drissi H., Hushka D., Aslam F., Nguyen Q., Buffone E., Koff A., et al. The cell cycle regulator p27kip1 contributes to growth and differentiation of osteoblasts. Cancer Res 59 (1999) 3705-3711
22. Thomas D.M., Johnson S.A., Sims N.A., Trivett M.K., Slavin J.L., Rubin B.P., et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 167 (2004) 925-934
23. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
24. Motti M.L., Califano D., Troncone G., De Marco C., Migliaccio I., Palmieri E., et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. Am J Pathol 166 (2005) 737-749
25. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
26. Liu B., Shi Z.L., Feng J., and Tao H.M. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt. Cell Biol Int 32 (2008) 494-501
27. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275 (2000) 11397-11403
28. Kucab J.E., Lee C., Chen C.S., Zhu J., Gilks C.B., Cheang M., et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7 (2005) R796-807
29. Wu T., Leng J., Han C., and Demetris A.J. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3 (2004) 299-307
30. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., and Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7 (2005) R422-R435
31. Wang X., Hu J., and Price S.R. Inhibition of PI3-kinase signaling by glucocorticoids results in increased branched-chain amino acid degradation in renal epithelial cells. Am J Physiol Cell Physiol 292 (2007) C1874-C1879
32. Failor K.L., Desyatnikov Y., Finger L.A., and Firestone G.L. Glucocorticoid-induced degradation of glycogen synthase kinase-3 protein is triggered by serum- and glucocorticoid-induced protein kinase and Akt signaling and controls beta-catenin dynamics and tight junction formation in mammary epithelial tumor cells. Mol Endocrinol 21 (2007) 2403-2415
33. Fujita T., Fukuyama R., Enomoto H., and Komori T. Dexamethasone inhibits insulin-induced chondrogenesis of ATDC5 cells by preventing PI3K-Akt signaling and DNA binding of Runx2. J Cell Biochem 93 (2004) 374-383
34. Chrysis D., Zaman F., Chagin A.S., Takigawa M., and Savendahl L. Dexamethasone induces apoptosis in proliferative chondrocytes through activation of caspases and suppression of the Akt-phosphatidylinositol 3′-kinase signaling pathway. Endocrinology 146 (2005) 1391-1397
35. Yasumaru M., Tsuji S., Tsujii M., Irie T., Komori M., Kimura A., et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res 63 (2003) 6726-6734
36. Tan A., Nakamura H., Kondo N., Tanito M., Kwon Y.W., Ahsan M.K., et al. Thioredoxin-1 attenuates indomethacin-induced gastric mucosal injury in mice. Free Radic Res 41 (2007) 861-869
37. Wang F.S., Ko J.Y., Yeh D.W., Ke H.C., and Wu H.L. Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology 149 (2008) 1793-1801
38. Collado M., Medema R.H., Garcia-Cao I., Dubuisson M.L., Barradas M., Glassford J., et al. Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 275 (2000) 21960-21968
39. Liu X., Shi Y., Woods K.W., Hessler P., Kroeger P., Wilsbacher J., et al. Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora a kinase expression. Neoplasia 10 (2008) 828-837
40. Lin H.P., Kulp S.K., Tseng P.H., Yang Y.T., Yang C.C., and Chen C.S. Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol Cancer Ther 3 (2004) 1671-1680
41. Greer E.L., and Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24 (2005) 7410-7425
42. Reagan-Shaw S., and Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. Cancer Res 66 (2006) 1062-1069
43. Fu Z., and Tindall D.J. FOXOs, cancer and regulation of apoptosis. Oncogene 27 (2008) 2312-2319
44. Adachi M., Osawa Y., Uchinami H., Kitamura T., Accili D., and Brenner D.A. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. Gastroenterology 132 (2007) 1434-1446
45. Brenkman A.B., de Keizer P.L., van den Broek N.J., van der Groep P., van Diest P.J., van der Horst A., et al. The peptidyl-isomerase Pin1 regulates p27kip1 expression through inhibition of Forkhead box O tumor suppressors. Cancer Res 68 (2008) 7597-7605
46. Dijkers P.F., Medema R.H., Pals C., Banerji L., Thomas N.S., Lam E.W., et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20 (2000) 9138-9148
47. Hu Y., Wang X., Zeng L., Cai D.Y., Sabapathy K., Goff S.P., et al. ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 16 (2005) 3705-3718
48. Lees S.J., Childs T.E., and Booth F.W. Age-dependent FOXO regulation of p27Kip1 expression via a conserved binding motif in rat muscle precursor cells. Am J Physiol Cell Physiol (2008)
49. Lynch R.L., Konicek B.W., McNulty A.M., Hanna K.R., Lewis J.E., Neubauer B.L., et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 3 (2005) 163-169
50. Nakao T., Geddis A.E., Fox N.E., and Kaushansky K. PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27(Kip1). Cell Cycle 7 (2008) 257-266
51. Arden K.C. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 41 (2006) 709-717
52. Chua C.C., Chua B.H., Chen Z., Landy C., and Hamdy R.C. Dexamethasone induces caspase activation in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 1642 (2003) 79-85
53. Suzuki N., and Hattori A. Bisphenol A suppresses osteoclastic and osteoblastic activities in the cultured scales of goldfish. Life Sci 73 (2003) 2237-2247
54. Viereck V., Grundker C., Blaschke S., Niederkleine B., Siggelkow H., Frosch K.H., et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab 88 (2003) 4206-4213
55. Clemett D., and Goa K.L. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 59 (2000) 957-980
56. Kovarik J.M., Purba H.S., Pongowski M., Gerbeau C., Humbert H., and Mueller E.A. Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: implications for coadministration. Pharmacotherapy 18 (1998) 1230-1236
57. Oberbauer R., Krivanek P., and Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet 24 (1993) 428-434
58. Minami S., Ohtani-Fujita N., Igata E., Tamaki T., and Sakai T. Molecular cloning and characterization of the human p27Kip1 gene promoter. FEBS Lett 411 (1997) 1-6
59. Inoue T., Kamiyama J., and Sakai T. Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 274 (1999) 32309-32317
60. Kim K.J., Park M.C., Choi S.J., Oh Y.S., Choi E.C., Cho H.J., et al. Determination of three-dimensional structure and residues of the novel tumor suppressor AIMP3/p18 required for the interaction with ATM. J Biol Chem 283 (2008) 14032-14040
61. Sakurai K., and Osumi N. The neurogenesis-controlling factor, Pax6, inhibits proliferation and promotes maturation in murine astrocytes. J Neurosci 28 (2008) 4604-4612
62. Tang X.Y., Li Y.F., and Tan S.M. Intercellular adhesion molecule-3 binding of integrin alphaL beta2 requires both extension and opening of the integrin headpiece. J Immunol 180 (2008) 4793-4804
63. Otsubo T., Akiyama Y., Yanagihara K., and Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 98 (2008) 824-831
64. Ali F., Hamdulay S.S., Kinderlerer A.R., Boyle J.J., Lidington E.A., Yamaguchi T., et al. Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1. J Thromb Haemost 5 (2007) 2537-2546
65. Wang Y.H., Ho M.L., Chang J.K., Chu H.C., Lai S.C., and Wang G.J. Microporation is a valuable transfection method for gene expression in human adipose tissue-derived stem cells. Mol Ther 17 (2009) 302-308
66. Morrison T.B., Weis J.J., and Wittwer C.T. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. BioTechniques 24 (1998) 954-958 960, 962
67. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, CA) 25 (2001) 402-408
68. Medema R.H., Kops G.J., Bos J.L., and Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404 (2000) 782-787
69. Wei Q., Miskimins W.K., and Miskimins R. The Sp1 family of transcription factors is involved in p27(Kip1)-mediated activation of myelin basic protein gene expression. Mol Cell Biol 23 (2003) 4035-4045
70. Sue Y.M., Chung C.P., Lin H., Chou Y., Jen C.Y., Li H.F., et al. PPARdelta-mediated p21/p27 induction via increased CREB-binding protein nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells. Am J Physiol Cell Physiol 297 (2009) C321-C329
71. Kwon T.K., Nagel J.E., Buchholz M.A., and Nordin A.A. Characterization of the murine cyclin-dependent kinase inhibitor gene p27Kip1. Gene 180 (1996) 113-120
72. Marinovic A.C., Zheng B., Mitch W.E., and Price S.R. Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1. J Biol Chem 277 (2002) 16673-16681
73. Marinovic A.C., Zheng B., Mitch W.E., and Price S.R. Tissue-specific regulation of ubiquitin (UbC) transcription by glucocorticoids: in vivo and in vitro analyses. Am J Physiol Renal Physiol 292 (2007) F660-F666
74. Grosch S., Tegeder I., Niederberger E., Brautigam L., and Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15 (2001) 2742-2744
75. Newton R., Seybold J., Kuitert L.M., Bergmann M., and Barnes P.J. Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. J Biol Chem 273 (1998) 32312-32321
76. Tsatsanis C., Androulidaki A., Venihaki M., and Margioris A.N. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38 (2006) 1654-1661